0000000000320432

AUTHOR

Crescenzo D'alterio

showing 2 related works from this author

A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.

2021

Platinum-based chemotherapy remains widely used in advanced non-small cell lung cancer (NSCLC) despite experimental evidence of its potential to induce long-term detrimental effects, including the promotion of pro-metastatic microenvironments. In this study, we investigated the interconnected pathways underlying the promotion of cisplatin-induced metastases. In tumor-free mice, cisplatin treatment resulted in an expansion in the bone marrow of CCR2+CXCR4+Ly6Chigh inflammatory monocytes (IMs) and an increase in lung levels of stromal SDF-1, the CXCR4 ligand. In experimental lung metastasis assays, cisplatin-induced IMs promoted the extravasation of tumor cells and the expansion of CD133+CXCR…

MaleReceptors CXCR4Stromal cellLung NeoplasmsSettore MED/08 - Anatomia PatologicaMonocytesMetastasisMiceCarcinoma Non-Small-Cell LungCell Line TumorDrug DiscoveryGeneticsMedicineSettore MED/05 - Patologia ClinicaAnimalsHumansDrug InteractionsAC133 AntigenNeoplasm MetastasisLung cancerMolecular BiologyPharmacologyCisplatinCXCR4 antagonistchemotherapy combination therapy inflammatory monocytes lung cancer stem cells metastasis peptide anti-CXCR4 SDF-1/CXCR4 axisbusiness.industrymedicine.diseasePrimary tumorXenograft Model Antitumor AssaysExtravasationChemokine CXCL12medicine.anatomical_structureRAW 264.7 CellsA549 CellsCancer researchNeoplastic Stem CellsMolecular MedicineBone marrowCisplatinbusinessPeptidesmedicine.drugMolecular therapy : the journal of the American Society of Gene Therapy
researchProduct

SDF-1/CXCR4 inhibition prevents paradoxical generation of cisplatin-induced pro-metastatic niches

2020

AbstractPlatinum-based chemotherapy remains widely used in advanced non-small cell lung cancer (NSCLC) despite its ineffectiveness in long-term control of metastasis.Here, we uncover the interconnected pathways subtending cisplatin-induced metastasis promotion.We report that cisplatin treatment of tumor-free mice results in bone-marrow expansion of CCR2+CXCR4+Ly6Chigh inflammatory monocytes (IM) concomitantly with increased levels in the lungs of stromal SDF-1, the CXCR4 ligand. In experimental metastasis assays, cisplatin-induced IM favor tumor cells extravasation and expansion of CD133+CXCR4+ metastasis initiating cells (MICs), facilitating lung metastasis formation. At the primary tumor,…

CisplatinChemotherapyStromal cellCombination therapybusiness.industrymedicine.medical_treatmentmedicine.diseaseCXCR4Primary tumorExtravasationMetastasisCancer researchMedicinebusinessmedicine.drug
researchProduct